These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8618963)

  • 21. Malignant hyperthermia.
    Hopkins PM; Gupta PK; Bilmen JG
    Handb Clin Neurol; 2018; 157():645-661. PubMed ID: 30459030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered E-C coupling in triads isolated from malignant hyperthermia-susceptible porcine muscle.
    el-Hayek R; Yano M; Antoniu B; Mickelson JR; Louis CF; Ikemoto N
    Am J Physiol; 1995 Jun; 268(6 Pt 1):C1381-6. PubMed ID: 7611356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of the skeletal muscle ryanodine receptor gene in malignant hyperthermia.
    MacLennan DH; Otsu K; Fujii J; Zorzato F; Phillips MS; O'Brien PJ; Archibald AL; Britt BA; Gillard EF; Worton RG
    Symp Soc Exp Biol; 1992; 46():189-201. PubMed ID: 1341035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abnormality in calcium release from skeletal sarcoplasmic reticulum of pigs susceptible to malignant hyperthermia.
    Nelson TE
    J Clin Invest; 1983 Sep; 72(3):862-70. PubMed ID: 6886007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Porcine malignant hyperthermia: critical temperatures for in vivo and in vitro responses.
    Nelson TE
    Anesthesiology; 1990 Sep; 73(3):449-54. PubMed ID: 2393129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postulated role of interdomain interaction between regions 1 and 2 within type 1 ryanodine receptor in the pathogenesis of porcine malignant hyperthermia.
    Murayama T; Oba T; Hara H; Wakebe K; Ikemoto N; Ogawa Y
    Biochem J; 2007 Mar; 402(2):349-57. PubMed ID: 17107340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of chlorocresol vs caffeine on muscle contracture in malignant hyperthermia susceptible patients].
    Ben-Abraham R; Krivosic-Horber RM; Haudcoeur G; Perel A; Adnet PJ
    Harefuah; 1997 Jun; 132(12):839-41, 911. PubMed ID: 9264187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heat production during anesthetic-induced malignant hyperthermia.
    Nelson TE
    Biosci Rep; 2001 Apr; 21(2):169-79. PubMed ID: 11725865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ryanodine receptor type 1 (RyR1) possessing malignant hyperthermia mutation R615C exhibits heightened sensitivity to dysregulation by non-coplanar 2,2',3,5',6-pentachlorobiphenyl (PCB 95).
    Ta TA; Pessah IN
    Neurotoxicology; 2007 Jul; 28(4):770-9. PubMed ID: 17023049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Slow calcium current is not reduced in malignant hyperthermic porcine myotubes.
    Gallant EM; Balog EM; Beam KG
    Muscle Nerve; 1996 Apr; 19(4):450-5. PubMed ID: 8622723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Malignant hyperthermia: fatigue characteristics of skeletal muscle.
    Balog EM; Enzmann NR; Gallant EM
    Muscle Nerve; 2000 Feb; 23(2):223-30. PubMed ID: 10639615
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of the calcium release channel of skeletal muscle sarcoplasmic reticulum in malignant hyperthermia.
    MacLennan DH; Chen SR
    Ann N Y Acad Sci; 1993 Dec; 707():294-304. PubMed ID: 9137560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Malignant hyperthermia: update on susceptibility testing.
    Litman RS; Rosenberg H
    JAMA; 2005 Jun; 293(23):2918-24. PubMed ID: 15956637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia.
    MacLennan DH; Duff C; Zorzato F; Fujii J; Phillips M; Korneluk RG; Frodis W; Britt BA; Worton RG
    Nature; 1990 Feb; 343(6258):559-61. PubMed ID: 1967823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Malignant hyperthermia: pathophysiology, clinical presentation, and treatment.
    McCarthy EJ
    AACN Clin Issues; 2004; 15(2):231-7. PubMed ID: 15461040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abnormal uptake and release of Ca2+ ions from human malignant hyperthermia-susceptible sarcoplasmic reticulum.
    O'Sullivan GH; McIntosh JM; Heffron JJ
    Biochem Pharmacol; 2001 Jun; 61(12):1479-85. PubMed ID: 11377377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A case of discordance between genotype and phenotype in a malignant hyperthermia family.
    Fortunato G; Carsana A; Tinto N; Brancadoro V; Canfora G; Salvatore F
    Eur J Hum Genet; 1999; 7(4):415-20. PubMed ID: 10352931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility.
    Monnier N; Kozak-Ribbens G; Krivosic-Horber R; Nivoche Y; Qi D; Kraev N; Loke J; Sharma P; Tegazzin V; Figarella-Branger D; Roméro N; Mezin P; Bendahan D; Payen JF; Depret T; Maclennan DH; Lunardi J
    Hum Mutat; 2005 Nov; 26(5):413-25. PubMed ID: 16163667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct effects on Ca2+ handling caused by malignant hyperthermia and central core disease mutations in RyR1.
    Dirksen RT; Avila G
    Biophys J; 2004 Nov; 87(5):3193-204. PubMed ID: 15347586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization.
    Guis S; Figarella-Branger D; Monnier N; Bendahan D; Kozak-Ribbens G; Mattei JP; Lunardi J; Cozzone PJ; Pellissier JF
    Arch Neurol; 2004 Jan; 61(1):106-13. PubMed ID: 14732627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.